Clinical Trial

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer

Study acronym: PEARL-C1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The PEARL-C1 trial is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-24; most recent amendment 2026-06-19.
Status change: Not Yet Recruiting → Recruiting 2026-06-19
Trial Details
NCT Number NCT07048743
Lead Sponsor University Health Network, Toronto
Conditions Caregiver Distress
Enrollment 15 participants
Start Date 2025-07-16
Primary Completion 2027-12-02 (estimated)
Study Completion 2027-12-02 (estimated)
Updated on ClinicalTrials.gov 2026-06-23